Is Kardigan, Inc. (KARD) a Buy, Sell, or Hold?
NASDAQ : KARD
Kardigan, Inc.
$21.02 USD
-$0.97 (-4.41%)
- Volume
- 378.17K
- Average Volume
- 968.29K
- Market Capitalization
- $1.88B
- P/E Ratio
- Dividend Yield
- %
- Price Target
- $38.50
- Year High
- $27.00
- Year Low
- $16.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Tassos Gianakakos |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KARD |
| CUSIP | 485925101 |
| CIK | 0002123613 |
| Web | http://www.kardigan.bio |
| Phone | (415) 573-3220 |
| Currency | USD |
| Employees | 241 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | |
| Payout Ratio | |
| Current Ratio | |
| Quick Ratio | |
| Cash Ratio |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | |
| Cash Flow | |
| Price / Cash Flow | |
| Price / Book |
Price Target and Rating
| Average Stock Price Forecast | $38.50 |
| High Stock Price Forecast | $40.00 |
| Low Stock Price Forecast | $37.00 |
| Forecast Upside/Downside | -45.40% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | |
| Trailing P/E Ratio | |
| PEG Ratio | |
| P/E Growth | |
| Net Income | -$ |
| Net Margin | % |
| Pretax Margin | % |
| Return on Equity | % |
| Return on Assets | % |
Financials Score
| AltmanZ Score | |
| Piotroski Score | |
| Working Capital | - |
| Total Assets | - |
| Ebit | - |
| Market Cap | - |
| Total Liabilities | - |
Poll Results
About Kardigan, Inc. (NASDAQ:KARD) Stock
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ. ...
2026-06-22 17:03:00
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.
Kardigan rises in Nasdaq debut after upsized $400 million IPO
2026-06-18 12:49:22
Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.S. initial public offering.
Kardigan Announces Pricing of Upsized Initial Public Offering
2026-06-17 20:30:00
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16 per share. The gross proceeds from the offering are expected to be $400 million, before unde.
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
2026-06-11 06:33:30
Kardigan is targeting a valuation of up to $1.4 billion in its initial public offering in the United States, the drug developer said on Thursday.
Kardigan Begins Process For IPO On Cardiovascular Treatments Promise
2026-06-02 09:48:25
Kardigan, Inc. (KARD) is a clinical-stage biopharma targeting various cardiovascular disease treatments with a pipeline led by Danicamtiv, now in Phase 2b/3 trials. KARD leverages its Prolario AI platform to optimize clinical trial design, patient identification, and data collection, aiming for improved outcomes and efficiency. The company is well-capitalized with $287 million in cash and strong backing from top-tier life science VCs, positioning it for robust pipeline advancement.
Frequently Asked Questions
-
What is the current Kardigan, Inc. (KARD) stock price?
-
Kardigan, Inc.(NASDAQ:KARD) stock price is $21.02 in the last trading session. During the trading session, KARD stock reached the peak price of $27 while $16.25 was the lowest point it dropped to. The percentage change in KARD stock occurred in the recent session was --4.41% while the dollar amount for the price change in KARD stock was -$0.97.
-
KARD's industry and sector of operation?
-
The NASDAQ listed KARD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KARD?
-
Donald Mackenzie | Chief Technical Operations Officer
Bob McDowell | Co-founder & Scientific Advisor
Elizabeth McNally | Co-Founder
Leslie A. Leinwand | Co-Founder
Jay Edelberg | Co-founder & Chief Medical Officer -
How many employees does KARD have?
-
Number of KARD employees currently stands at 241. KARD operates from 506 Carnegie Center Drive, Princeton, NJ 08540, US.
-
Link for KARD official website?
-
Official Website of KARD is: http://www.kardigan.bio
-
How do I contact KARD?
-
KARD could be contacted at phone #(415) 573-3220 and can also be accessed through its website. KARD operates from 506 Carnegie Center Drive, Princeton, NJ 08540, US.
-
How many shares of KARD are traded daily?
-
The average number of KARD shares traded daily for last 3 months was 968.29K.
-
What is the market cap of KARD currently?
-
The market value of KARD currently stands at $1.88B with its latest stock price at $21.02